Accepted for Publication: September 28, 2021.
Published: November 24, 2021. doi:10.1001/jamanetworkopen.2021.36030
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Kamar N et al. JAMA Network Open.
Corresponding Author: Nassim Kamar, MD, PhD, Department of Nephrology and Organ Transplantation, Toulouse University Hospital, TSA 50032, 31059 Toulouse Cedex 9, France (firstname.lastname@example.org).
Author Contributions: Dr Kamar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kamar, Marion, Del Bello.
Acquisition, analysis, or interpretation of data: Kamar, Abravanel, Marion, Romieu-Mourez, Couat, Izopet.
Drafting of the manuscript: Kamar.
Critical revision of the manuscript for important intellectual content: Kamar, Abravanel, Marion, Couat, Del Bello, Izopet.
Statistical analysis: Kamar, Couat.
Administrative, technical, or material support: Abravanel, Romieu-Mourez, Couat.
Supervision: Abravanel, Del Bello, Izopet.
Conflict of Interest Disclosures: Dr Kamar reported receiving speaker fees and participating in advisory boards for AbbVie, Astellas, Biotest, CSL Behring, Chiesi, Merck Sharp and Dohme, Neovii, Novartis Pharma, Sanofi, Sandoz, Shire, and Takeda and receiving personal fees from AbbVie, Astellas, Biotest, CSL Behring, Chiesi, Merck Sharp and Dohme, Neovii, Novartis Pharma, Sanofi, Sandoz, Shire, and Takeda outside the submitted work. No other disclosures were reported.
C , Herin
F , Da-Silva
et al. Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2. Clin Infect Dis
. Published online August 12, 2021. doi:10.1093/cid/ciab705